title: A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives.
abstract: The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l-lactide based topcoat mixture. The strut thickness is 150μm and the scaffold has platinum-iridium radiopaque markers at both ends. Radial support is available during the early time period to prevent recoil. The scaffold biodegrades within 1year (>90% reduction in molecular weight) and then completely bioresorbs within 2years. The DESolve® scaffold permits a wide range of expansion with a consequently reduced risk for strut fracture. Lumen and scaffold enlargement is observed within 3-6months in both preclinical and clinical studies potentially allowing for the scaffolded region to respond to vasoactive stimuli. The device has a unique property of self-correction observed in bench top studies, which in clinical practice has the potential to eliminate minor malapposition following deployment.
authors.affiliation: University of Giessen, Medizinische Klinik I, Department of Cardiology, Giessen, Germany.
authors.forename: Holger M
authors.initials: HM
authors.lastname: Nef
authors.affiliation: Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Wiebe
authors.affiliation: National Heart Centre Singapore, Singapore.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Foin
authors.affiliation: Friedrich-Alexander University Erlangen-Nürnberg, University Hospital Erlangen, Department of Cardiology, Erlangen, Germany. Electronic address: florian.blachutzik@uk-erlangen.de.
authors.forename: Florian
authors.initials: F
authors.lastname: Blachutzik
authors.affiliation: University of Giessen, Medizinische Klinik I, Department of Cardiology, Giessen, Germany.
authors.forename: Oliver
authors.initials: O
authors.lastname: Dörr
authors.affiliation: Elixir Medical, 870 Hermosa Drive, Sunnyvale, CA 94965, USA.
authors.forename: Sara
authors.initials: S
authors.lastname: Toyloy
authors.affiliation: University of Giessen, Medizinische Klinik I, Department of Cardiology, Giessen, Germany.
authors.forename: Christian W
authors.initials: CW
authors.lastname: Hamm
mesh_terms: D020341:Absorbable Implants / Q000706:statistics & numerical data*; D017023:Coronary Angiography / Q000379:methods; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000592:standards* / Q000639:trends; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D018942:Macrolides / Q000494:pharmacology*; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D018570:Risk Assessment; D054457:Tissue Scaffolds; D016896:Treatment Outcome; D014654:Vascular Patency / Q000502:physiology
chemical_list: D018942:Macrolides; C534800:novolimus
keywords: Coronary artery disease; Novolimus-eluting bioresorbable vascular scaffold; Percutaneous coronary intervention